1-20 of 27
Houry Leblebjian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Keeping an Eye on Belantamab: Characterizing Ocular Toxicities

Shahrier Hossain, Omar Marzouk, Houry Leblebjian, Robert A. Redd, Jacob Laubach
Journal: Blood
Blood (2022) 140 (Supplement 1): 13206–13207.
https://doi.org/10.1182/blood-2022-166720
Published: 2022
Journal Articles

A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Kelsey Tague, Veronica Romines, Amada Metivier, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 2749.
https://doi.org/10.1182/blood-2021-149787
Published: 2021
Journal Articles

Mapping Myeloma: A Roadmap of Daratumumab Use in Clinical Pathways

Shahrier Hossain, Houry Leblebjian, David M Jackman, Jacob P. Laubach, Clifton C. Mo, Paul G. Richardson, Emily Foster, Ariel Martin-Quashie, Robert Redd, Omar Nadeem
Journal: Blood
Blood (2021) 138 (Supplement 1): 4021.
https://doi.org/10.1182/blood-2021-149482
Published: 2021
Journal Articles

B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Julia Prescott, Amada Metivier, Kelsey Tague, Veronica Romines, Meredith Bertoni, Alexandra Savell, Rebekah Medina, Alexandra Distaso, Houry Leblebjian, Clifton C. Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 4782.
https://doi.org/10.1182/blood-2021-148023
Published: 2021
Journal Articles

Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma

Eno Inyang, Anil Aktas-Samur, Nikhil C. Munshi, Houry Leblebjian
Journal: Blood
Blood (2021) 138 (Supplement 1): 666.
https://doi.org/10.1182/blood-2021-146605
Published: 2021
Journal Articles

A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma

Catherine R. Marinac, Robert A. Redd, Julia Prescott, Alexandra Savell, Courtney Igne, Jacob P. Laubach, Adam S. Sperling, Aric D. Parnes, Houry Leblebjian, Paul G. Richardson, Irene M. Ghobrial, Omar Nadeem
Journal: Blood
Blood (2021) 138 (Supplement 1): 1659.
https://doi.org/10.1182/blood-2021-151878
Published: 2021
Journal Articles

A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Omar Nadeem, Robert A. Redd, Michael Z. Koontz, Jeffrey V. Matous, Andrew J. Yee, Jeffrey A. Zonder, Andrew Kin, Jacalyn Rosenblatt, Julia Prescott, Kelsey Tague, Veronica Romines, Meredith Bertoni, Amada Metivier, Rebekah Medina, Alexandra Savell, Houry Leblebjian, Alexandra Distaso, Clifton C Mo, Jacob P. Laubach, Adam S. Sperling, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 1649.
https://doi.org/10.1182/blood-2021-149797
Published: 2021
Journal Articles

High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

Habib El-Khoury, Jean-Baptiste Alberge, Hadley Barr, Ciara Murphy, D.J. Sakrikar, Tara Krause, David Barnidge, Mark Bustoros, Houry Leblebjian, Annie Cowan, Maya Davis, Julia Amstutz, Jacqueline Perry, Cody J. Boehner, Elizabeth D. Lightbody, Tarek H Mouhieddine, Romanos Sklavenitis-Pistofidis, Mark C Perkins, Stephen Harding, Prashant Kapoor, Clifton C. Mo, David L. Murray, Ivan M. Borrello, Gad Getz, Timothy R Rebbeck, Catherine R. Marinac, Irene M. Ghobrial
Journal: Blood
Blood (2021) 138 (Supplement 1): 152.
https://doi.org/10.1182/blood-2021-149868
Published: 2021
Journal Articles

Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study

Grace Hwang, PharmD, Audrea Szabatura, PharmD, Houry Leblebjian, PharmD, BCOP, Anil Aktas-Samur, PhD, Jacob P. Laubach, MD, Aric D. Parnes, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–16.
https://doi.org/10.1182/blood-2020-140175
Published: 2020
Journal Articles

Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)

Eno Inyang, PharmD, BCPS, Nikhil C. Munshi, MD, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP
Journal: Blood
Blood (2020) 136 (Supplement 1): 11.
https://doi.org/10.1182/blood-2020-136342
Published: 2020
Journal Articles

Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma

Shawn O. Streeter, PharmD, Omar Nadeem, MD, Paul G. Richardson, MD, Jacob P. Laubach, MD, Clifton C. Mo, MD, Kimberly Noonan, RN, NP, AOCN, Mary McKenney, NP, Tina Flaherty, ANP-BC, AOCN, Virginia Dalton, MS, APRN, Anil Aktas-Samur, PhD, Houry Leblebjian, PharmD, BCOP
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-143385
Published: 2020
Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Mark Bustoros, MD, Omar Nadeem, MD, Adam S Sperling, MD PhD, Giada Bianchi, MD, Lily Ardente, BS, Robert A. Redd, MS, Julia Prescott, NP, Erin Frey, RN, Kathleen Guimond, RN, Rachel Styles, BS, Kalvis Hornburg, BA, Alexandra Savell, BS, Nang Kham Su, BA, Govind Bindra, BA, Cody J Boehner, BS, Kaitlen Reyes, DNP, Houry Leblebjian, PharmD, Diane Warren, Nikhil C. Munshi, MD, Jacob P. Laubach, MD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Irene M. Ghobrial, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 580.
https://doi.org/10.1182/blood-2019-128519
Published: 2019
Journal Articles

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Patrick McBride, PharmD, Houry Leblebjian, PharmD, Paul Richardson, Jacob Laubach, MD, Hillary Prescott, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3234.
https://doi.org/10.1182/blood-2018-99-111361
Published: 2018
Journal Articles

Improving Rates of Venous Thromboembolism Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs

Houry Leblebjian, PharmD, Joanna Hamilton, MA, MS, Sydney Smith, PharmD, Jacob Laubach, MD, Nancy Berliner, MD, Aric Parnes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2235.
https://doi.org/10.1182/blood-2018-99-115436
Published: 2018
Journal Articles

Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule

Elaine Xiang, PharmD, Hillary Prescott, PharmD, Jacob Laubach, MD, Paul Richardson, Kaitlen Reyes, NP, Irene M. Ghobrial, MD, Houry Leblebjian, PharmD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2024.
https://doi.org/10.1182/blood-2018-99-111191
Published: 2018
Journal Articles

Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Mark Bustoros, MD, Chia-jen Liu, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Kathleen Guimond, RN, Rachel Styles, Alexandra Savell, BS, Brianna Berrios, BS, Diane Warren, Henry Dumke, BS, Bradley Rivotto, BS, Patrick Henrick, BS, Emily Scranton, NP, Houry Leblebjian, PharmD, Kirsten Meid, MPH, Robert L. Schlossman, MD, Nikhil Munshi, MD, Jacob Laubach, MD, Kenneth C. Anderson, MD, Paul Richardson, Irene M. Ghobrial, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 804.
https://doi.org/10.1182/blood-2018-99-117871
Published: 2018
Journal Articles

Impact of Bone Marrow Biopsy on Risk Stratification of Low-Risk IgG MGUS Patients

Mark Bustoros, Eftathios Kastritis, Chia-Jen Liu, MD PhD, Nikolaos Kanellias, David Liu, MD MPH, MS, Maria Gavriatopoulou, Adriana Perilla Glen, Maria Roussou, Patrick Henrick, BS, Magdalini Migkou, Alexandra Savell, BS, Kimberly Noonan, NP, Kaitlen Reyes, NP, Bradley Rivotto, BS, Houry Leblebjian, PharmD, Claudia Paba-Prada, MD, Dimitrios C. Ziogas, Jacob Laubach, MD, Robert L. Schlossman, MD, Kenneth C Anderson, MD, Paul G Richardson, MD, Irene M Ghobrial, MD, Meletios A. Dimopoulos
Journal: Blood
Blood (2017) 130 (Supplement 1): 5397.
https://doi.org/10.1182/blood.V130.Suppl_1.5397.5397
Published: 2017
Journal Articles

Adverse Events in Patients with Cancer Treated with Direct Oral Anticoagulants and Cancer Therapy

Huong L Truong, PharmD, Audrea Szabatura, PharmD, Houry Leblebjian, PharmD, Christy Harris, PharmD, Jean M. Connors, BA,MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2396.
https://doi.org/10.1182/blood.V130.Suppl_1.2396.2396
Published: 2017
Journal Articles

Direct Oral Anticoagulants in Anti-Phospholipid Syndrome

Houry Leblebjian, PharmD, Aric Parnes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2145.
https://doi.org/10.1182/blood.V130.Suppl_1.2145.2145
Published: 2017
Journal Articles

Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression

Mark Bustoros, Jihye Park, PhD, Karma Ziad Salem, MD, Chia-Jen Liu, MD PhD, Marzia Capelletti, PhD, Daisy Huynh, BS, MS, Yu-Tzu Tai, PhD, Tarek H Mouhieddine, MD, Samuel Freeman, Gavin Ha, PhD, Justin Rhoades, Sarah Reed, Gregory Gydush, Denisse Rotem, Adriana Perilla Glen, Patrick Henrick, BS, Aaron Caola, Bradley Rivotto, BS, Alexandra Savell, BS, Kimberly Noonan, NP, Kaitlen Reyes, NP, Antonio Sacco, Cody J Boehner, Houry Leblebjian, PharmD, David Liu, MD MPH, MS, Elizabeth A Morgan, MD, Aldo M. Roccaro, Claudia Paba-Prada, MD, Eliezer Van Allen, MD, Christopher Love, Viktor Adalsteinsson, PhD, Jacob Laubach, MD, Robert Schlossman, MD, Nikhil Munshi, MD, Paul G Richardson, MD, Kenneth C Anderson, MD, Shaji K Kumar, MD, Gad Getz, PhD, Irene M Ghobrial, MD, Salomon Manier, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 392.
https://doi.org/10.1182/blood.V130.Suppl_1.392.392
Published: 2017